我院2009–2012年核苷类抗病毒药物的利用分析

Utilization analysis of nucleoside antiviral drug in our hospital during 2009 – 2012

目的:分析我院2009–2012年核苷类抗病毒药物的用药情况,总结其用药特点及变化趋势,为临床合理用药提供参考。方法:采用限定日剂量(DDD)方法,对核苷类抗病毒药物的用药频度(DDDs)、消耗金额、日用药金额(DDC)等指标进行统计分析。结果:我院2009–2012年核苷类抗病毒药物的消耗总金额呈现逐年上升趋势。其中,恩替卡韦年平均消耗金额为2 601.3万元,约占核苷类抗病毒药物的56%,远高于拉米夫定、阿德福韦酯和替比夫定;拉米夫定所占份额呈逐年下降趋势。四个药物的DDC均稳中有降。结论:我院核苷类抗病毒药物的总消耗量逐年增加,恩替卡韦用量增幅明显,阿德福韦酯和替比夫定相对稳定,拉米夫定有所下降。

Objective： To analyze the application of nucleoside antiviral drugs in our hospital from 2009 to 2012, discuss the features and changing trend, in order to improve the clinical rational use of nucleoside antiviral drugs. Methods： The DDDs, consumption sum and DDC of nucleoside antiviral drugs were analyzed during the period of 2009 - 2012. Results： The consumption sum of nucleoside antiviral drugs increased year by year in our hospital. The average consumption of entecavir per year was about 26.013 million Yuan and its constituent ratio was 56% in the consumption of nucleoside antiviral drugs, which was higher than lamivudine, adefovir and telbivudine. The consumption ratio of lamivudine decreased year by year. The DDC of all the drugs decreased slowly. Conclusion： The total consumption of nucleoside antiviral drugs increased year by year in our hospital. Among these drugs, the consumption of entecavir increased significantly, adefovir and telbivudine kept stable, while lamivudine decreased.